Org 28611
Org 28611 (SCH-900,111) is a drug developed by Organon International which acts as a potent cannabinoid receptor full agonist at both the CB and CB receptors. It was developed with the aim of finding a water-soluble cannabinoid agonist suitable for intravenous use as an analgesic, and while it achieved this aim and has progressed as far as Phase II clinical trials in humans as both a sedative and an analgesic, results against the comparison drugs (midazolam and morphine respectively) were not particularly favourable in initial testing.